AZ COMPLETES AGREEMENT WITH PERRIGO

RNS Number : 1527J
AstraZeneca PLC
15 December 2015
 



 

ASTRAZENECA COMPLETES AGREEMENT WITH PERRIGO FOR RIGHTS TO ENTOCORT® IN THE US

AstraZeneca today announced that it has completed its agreement with Perrigo Company plc for the divestment of US rights to Entocort® (budesonide), a gastroenterology medicine for patients with mild to moderate Crohn's disease, an area of medicine outside AstraZeneca's strategic focus.

 

Upon completion of the agreement, Perrigo paid AstraZeneca $380 million to acquire the rights to sell Entocort capsules and the authorised generic Entocort capsules marketed by Par Pharmaceuticals. The transaction does not include the transfer of any AstraZeneca employees or facilities.

 

The agreement completes the global divestment of Entocort, following the agreement entered into in July 2015 with Tillotts Pharma AG, part of the Zeria Group, for the divestment of global rights to Entocort outside the US. The divestment further emphasises AstraZeneca's strategic focus on three main therapy areas. The transaction does not impact AstraZeneca's financial guidance for 2015.

 

About AstraZeneca

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology - as well as in infection and neuroscience. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

 

CONTACTS

 

Media Enquiries

 

 

 


Esra Erkal-Paler

 

UK/Global

+44 20 7604 8030

Neil Burrows

UK/Global

+44 20 7604 8032

Vanessa Rhodes

 

UK/Global

+44 20 7604 8037

Karen Birmingham

UK/Global

+44 20 7604 8120

Jacob Lund

 

Sweden

+46 8 553 260 20

Michele Meixell

US

+1 302 885 2677

Investor Enquiries



UK



Thomas Kudsk Larsen

 

Oncology

+44 7818 524185

Eugenia Litz

RIA

 

+44 7884 735627

Nick Stone

CVMD

 

+44 7717 618834

Craig Marks

Finance

+44 7881 615764

Christer Gruvris

 

Consensus Forecasts

+44 7827 836825

US



Lindsey Trickett

Oncology, ING

+1 240 543 7970

Mitch Chan

Oncology

+1 240 477 3771

Dial / Toll-Free


 +1 866 381 7277

 

Key: RIA - Respiratory, Inflammation and Autoimmunity, CVMD - Cardiovascular and Metabolic Disease,

ING - Infection, Neuroscience and Gastrointestinal





15 December 2015

 

-ENDS-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTABITMBIBBLA

Companies

AstraZeneca (AZN)
UK 100

Latest directors dealings